A global Alzheimer’s research push is using open proteomics and AI-enabled discovery to profile large plasma datasets as researchers look for improved detection of Alzheimer’s and related neurodegenerative proteinopathies. One consortium initiative plans to generate a 21,000-sample plasma proteomic dataset using the Alamar platform. Separately, at AAIC 2026, conference coverage highlighted how tau is moving into the spotlight alongside amyloid, reflecting growing clinical interest in second-target strategies. Together, the efforts point to intensified biomarker and therapeutic focus on both target validation and measurable disease signals.